Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant in MDD With Insomnia
2025-524794-16-00Phase 4Authorised
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and Insomnia comparing Daridorexant with Placebo (2 arms). Primary endpoint: Insomnia Severity Index (ISI) score at 3 months. Planned start Oct 2026; status: authorised.
02
Drugs
daridorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on 2025-524794-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524794-16-00.